135 related articles for article (PubMed ID: 31642538)
1. Irinotecan-induced gastrointestinal damage impairs the absorption of dabigatran etexilate.
Hattori T; Imaoka A; Akiyoshi T; Ohtani H
Biopharm Drug Dispos; 2019 Nov; 40(9):315-324. PubMed ID: 31642538
[TBL] [Abstract][Full Text] [Related]
2. 5-Fluororacil-Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate.
Tsujii K; Hattori T; Imaoka A; Akiyoshi T; Ohtani H
J Pharm Sci; 2018 May; 107(5):1430-1433. PubMed ID: 29291414
[TBL] [Abstract][Full Text] [Related]
3. The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate.
Udomnilobol U; Jianmongkol S; Prueksaritanont T
Drug Metab Dispos; 2023 Sep; 51(9):1216-1226. PubMed ID: 37230768
[TBL] [Abstract][Full Text] [Related]
4. Digoxin absorption decreased independently of P-gp activity in rats with irinotecan-induced gastrointestinal damage.
Tsuchitani T; Akiyoshi T; Imaoka A; Ohtani H
J Pharm Health Care Sci; 2021 Jul; 7(1):24. PubMed ID: 34193275
[TBL] [Abstract][Full Text] [Related]
5. Improved oral bioavailability and therapeutic efficacy of dabigatran etexilate via Soluplus-TPGS binary mixed micelles system.
Hu M; Zhang J; Ding R; Fu Y; Gong T; Zhang Z
Drug Dev Ind Pharm; 2017 Apr; 43(4):687-697. PubMed ID: 28032534
[TBL] [Abstract][Full Text] [Related]
6. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
Eur J Pharm Sci; 2021 Oct; 165():105932. PubMed ID: 34260894
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
Shi J; Wang X; Nguyen JH; Bleske BE; Liang Y; Liu L; Zhu HJ
Biochem Pharmacol; 2016 Nov; 119():76-84. PubMed ID: 27614009
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Zhao Y; Hu ZY
Br J Pharmacol; 2014 Feb; 171(4):1043-53. PubMed ID: 24283665
[TBL] [Abstract][Full Text] [Related]
9. Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling.
Doki K; Neuhoff S; Rostami-Hodjegan A; Homma M
CPT Pharmacometrics Syst Pharmacol; 2019 Feb; 8(2):118-126. PubMed ID: 30659778
[TBL] [Abstract][Full Text] [Related]
10. Possible roles of intestinal P-glycoprotein and cytochrome P450 3A on the limited oral absorption of irinotecan.
Yamasaki K; Hidaka M; Kawano Y; Furuya Y; Ono H; Arimori K
J Pharm Pharmacol; 2021 Mar; 73(2):178-184. PubMed ID: 33793796
[TBL] [Abstract][Full Text] [Related]
11. Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling.
Wang N; Chen L; Li N; Xu G; Qi F; Zhu L; Liu W
Sci Rep; 2020 Jun; 10(1):9717. PubMed ID: 32546773
[TBL] [Abstract][Full Text] [Related]
12. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis.
Laizure SC; Parker RB; Herring VL; Hu ZY
Drug Metab Dispos; 2014 Feb; 42(2):201-6. PubMed ID: 24212379
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Aging-Related Function Variations of P-gp Transporter in Old-Elderly Chinese CHF Patients Based on Modeling and Simulation.
Cui C; Qu Y; Sia JEV; Zhu Z; Wang Y; Ling J; Li H; Jiang Y; Pan J; Liu D
Clin Pharmacokinet; 2022 Dec; 61(12):1789-1800. PubMed ID: 36378486
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan-induced gastrointestinal damage alters the expression of peptide transporter 1 and absorption of cephalexin in rats.
Imaoka A; Hattori T; Akiyoshi T; Ohtani H
Biopharm Drug Dispos; 2023 Oct; 44(5):372-379. PubMed ID: 37507848
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition.
Chu X; Galetin A; Zamek-Gliszczynski MJ; Zhang L; Tweedie DJ;
Clin Pharmacol Ther; 2018 Nov; 104(5):788-792. PubMed ID: 30238965
[No Abstract] [Full Text] [Related]
17. Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.
Kumar P; Gordon LA; Brooks KM; George JM; Kellogg A; McManus M; Alfaro RM; Nghiem K; Lozier J; Hadigan C; Penzak SR
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848011
[TBL] [Abstract][Full Text] [Related]
18. Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats.
Tian X; Chang Y; Wei J; Liu R; Wang L; Zhang J; Zhang X
J Pharm Pharmacol; 2019 May; 71(5):788-796. PubMed ID: 30663770
[TBL] [Abstract][Full Text] [Related]
19. Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation.
Laizure SC; Chen F; Farrar JE; Ali D; Yang B; Parker RB
Drug Metab Pharmacokinet; 2022 Dec; 47():100479. PubMed ID: 36375226
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study.
Halton JM; Lehr T; Cronin L; Lobmeyer MT; Haertter S; Belletrutti M; Mitchell LG
Thromb Haemost; 2016 Aug; 116(3):461-71. PubMed ID: 27357738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
